Sartorius becomes DFKI shareholder


The Göttingen based life science group and DFKI have previously been working together in a joint research laboratory

Sartorius becomes DFKI shareholder

Sartorius has become a shareholder of the German Research Center for Artificial Intelligence (DFKI).

Sartorius is the first life science company to join the group of DFKI shareholders as its 33rd member and has received a seat on the supervisory board. This role is filled by CTO Dr Oscar-Werner Reif.

Sartorius and DFKI are currently conducting research on deep learning algorithms and methods for image recognition of cells and organoids, analysis and modeling of biological systems, and for simulation and optimization of biopharmaceutical production processes.

In August 2019, the companies opened the Sartorius AI Lab (SAIL) on the DFKI campus. At this joint research laboratory, the use of artificial intelligence in Sartorius products and platform solutions is experimentally tested and further developed.

SAIL is also available to Sartorius cooperation partners and customers. The lab is successfully used for mutual training: Specialists from Sartorius work in the DFKI research ecosystem, for example, using its deep learning hardware.

SAIL is now being further extended, inter alia, by a special ‘wet lab’, which is a laboratory in which novel AI processes are combined directly with cellular and molecular biology experiments and can be practically tested.

“We are happy to take the next step in our partnership with Sartorius and look forward to extending it even further. At a time when research and development in medicine and biopharma is especially at the focus, the commitment of a successful global player like Sartorius as a regular DFKI partner underscores the high significance of our AI technologies for this important field,” said Professor Antonio Krüger, PhD, the Managing Director and Head of the Cognitive Assistants Research Department at DFKI.

Sign up for your free email newsletter

“I am convinced that this partnership will result in important innovations for our industry. AI can unfold its powerful capabilities, above all in the accelerated development of more efficient medical drug manufacturing processes. In the medium term, we moreover see the potential of using AI processes to develop active pharmaceutical ingredients faster and more cost-effectively than the time‑consuming and cost‑intensive trial‑and‑error processes that are common today, thus making new therapeutics available earlier and to more patients,” said Dr Joachim Kreuzburg, Executive Board Chairman and CEO of Sartorius.